Summary Significant Accounting Policies Parentheticals (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Summary Significant Accounting Policies Parentheticals
Amortization of deferred financing costs related to convertible debt	$ 4,835	$ 0
Company decided that the patents related to its former product ProAlgaZyme should be written off in the amount of		6,234
Research Expenses - Salaries and equipment related expenses	0	66,000
Clinical Studies expenses - fees, charges and related expenses	797,000	374,000
Compensation expenses recorded	43,667	264,024
Potentially dilutive securities consisted of common shares from convertible debentures	35,958,735	31,198,000
Convertible debentures and related accrued interest	12,117,873	14,828,876
Advertising and Public Relations costs are charged to operations when incurred	22,688	12,341
Company maintains cash balances at financial institutions which exceed the current Federal Deposit Insurance Corporation ("FDIC") limit	$ 250,000	$ 0